PNC Financial Services Group Inc. Sells 378 Shares of Vericel Corporation $VCEL

Key Takeaways:

• PNC sold 378 shares of Vericel Corporation during the first quarter.
• The sale represents an 8.2 percent reduction in its holding.
• After the transaction, PNC holds 4,251 Vericel shares.
• The move was disclosed in the bank’s latest SEC filing.
• Vericel trades on NASDAQ under the symbol VCEL and operates in biotechnology.

A Modest Portfolio Adjustment
PNC Financial Services Group Inc. has lightened its exposure to Vericel Corporation, according to its most recent filing with the Securities and Exchange Commission. The document, covering first-quarter activity, shows the bank sold 378 shares of the biotech company.

Reading the Numbers
Before the sale, PNC’s Vericel position stood at roughly 4,629 shares. The 378-share disposal amounts to an 8.2 percent trim, bringing the stake down to 4,251 shares.

Why the SEC Filing Matters
Regulatory filings serve as one of the few windows into institutional trading activity. In PNC’s case, the disclosure offers a timely snapshot of how one of the country’s largest banking groups is tuning its portfolio—even if the adjustment is relatively small.

Vericel at a Glance
Headquartered in Cambridge, Mass., Vericel develops and markets advanced cell therapies for sports-medicine and burn-care patients. The company’s stock trades on the NASDAQ under the symbol VCEL.

Scale and Significance
An 8.2 percent reduction is hardly a wholesale exit. With 4,251 shares still on its books, PNC remains invested in Vericel’s prospects while freeing up a modest slice of capital for other uses.

Looking Ahead
Neither PNC nor Vericel commented in the filing, which focused solely on share counts. For now, the numbers tell the story: a small but notable recalibration of a biotech position by one of America’s banking mainstays.